A federal judge in Virginia ruled that the patent for Pfizer’s Celebrex expires in May.
A US federal judge in Virginia has given Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) the go-ahead to begin marketing a generic version of arthritis treatment Celebrex after ruling that the drug’s patent expires in May. Pfizer Inc. (NYSE: PFE) had been seeking to extend the patent of the blockbuster drug, which has annual sales of $3 billion, through to December 2015.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
Published by Globes [online], Israel business news – www.globes-online.com